Development and characterization of a novel model of ibrutinib resistance in Chronic Lymphocytic Leukemia (CLL) that displays sensitivity to PI3K inhibition

Thumbnail Image
Date
2021
Authors
Ehiremen, Godsent
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
BACKGROUND: Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy driven by a hyperactive B-cell receptor pathway (BCR-P). BCR signalling includes Bruton’s tyrosine kinase (BTK) activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2)-mediated proliferation via phospholipase C gamma 2 (PLCγ2), and phosphatidylinositol-3-Kinaseδ-Protein Kinase B (PI3Kδ-AKT) signalling promoting cell survival. The BTK inhibitor ibrutinib revolutionized CLL treatment; unfortunately, resistance is now on the rise, creating the need for a better understanding of the effects of long-term ibrutinib use. This project aims to establish and characterize a cell line model of ibrutinib resistance in order to identify cell signalling events and other changes induced by long-term ibrutinib use. METHODS: The BJAB cell line known to partly mimic CLL cell responses in vitro, was used for all investigations. Ibrutinib-resistant BJAB (IBR102) cells were created via a chronic dose-escalation approach. BJAB and IBR102 cells were treated with the BCR-P inhibitors ibrutinib (BTK), idelalisib (PI3Kδ), copanlisib (PI3Kα/β/δ/γ) and ravoxertinib (ERK1/2) alone and in combinations for 72 hours. Combinations were assessed for synergistic/additive/antagonistic cell death via flow cytometry and western blot was used for protein expression analyses. RESULTS: IBR102 cells were resistant to all BCR-P inhibitors used. Synergism in cell viability reduction was observed in ibrutinib-idelalisib/copanlisib combinations. Ravoxertinib displayed antagonism in both BJAB and IBR102 cells (to a lesser extent) when combined with all inhibitors used. Protein analysis showed PI3K-AKT-mediated ERK activation and 45% less baseline activity of ERK in IBR102 relative to BJABs; BTK activation was abolished in IBR102 cells. Ibrutinib-idelalisib combination resulted in a statistically significant synergistic reduction in ERK activation in both cell lines, but also AKT activation in BJAB cells. Notably, ibrutinib-idelalisib was shown to be synergistic in patient-derived CLL cells, and transcriptomic analysis showed that IBR102 cells expressed reduced levels of BCR, PI3K-AKT and MAPK pathway targets. CONCLUSION: Our work on IBR102 cells shows a new mechanism of ibrutinib resistance characterized by BCR pathway rewiring. We also provide evidence for an additional benefit on combining ibrutinib and a PI3K inhibitor in primary CLL cells. In summary, we propose a novel mechanism of ibrutinib resistance and define combination therapies against this resistance.
Description
Keywords
Chronic Lymphocytic Leukemia, Ibrutinib, Idelalisib, B-cell receptor (BCR) Pathway, CLL, Synergy, BJAB cells, Bruton's tyrosine kinase (BTK), Burkitt's lymphoma, Ibrutinib resistance, Mitogen-associated protein kinase (MAPK) pathway, Phosphatidyl-inositol-3-kinase (PI3K), Small molecule inhibitor, PI3K-AKT Pathway
Citation